Preparation,characterization, photocytotoxicity assay of PLGA nanoparticles containing zinc (II) phthalocyanine for photodynamic therapy use

Nanoparticles containing Zinc (II) Phthalocyanine (ZnPc) were prepared by a spontaneous emulsification diffusion method utilizing poly-(D,L lactic-co-glycolic acid) (PLGA), characterized and available in cellular culture. The process yield and encapsulation efficiency were 60% and 80%, respectively. The nanoparticles have a mean diameter of 200?nm, a narrow size distribution with polydispersive index of 0.15, smooth surface and spherical shape. ZnPc loaded nanoparticles maintain their photophysical behaviour after the encapsulation process. Photosensitizer released from nanoparticles was sustained with a burst effect of 10% for 3 days. The photocytotoxicity was evaluated on P388-D1 cells. They were incubated with ZnPc loaded Np by 6?h and exposed to light (675?nm) for 120?s, and light dose of 30?J?cm^?2. After 24?h of incubation, the cellular viability was determined, obtaining 60% of cellular death. All the physical-chemical and photobiological measurements performed allowed one conclude that ZnPc loaded PLGA nanoparticles are a promising drug delivery system for PDT.     

The necessity for the coating of perfluorodecalin-filled poly(lactide-co-glycolide) microcapsules in the presence of physiological cholate concentrations: Tetronic-908 as an exemplary polymeric surfactant

Recently, we demonstrated that biodegradable poly(lactide-co-glycolide) (PLGA) micro- and nanocapsules with a liquid content of perfluorodecalin are principally useful for the development of artificial oxygen carriers. In order to solve a decisive and well-known problem with PLGA microcapsules, i.e. the spontaneous agglomeration of the capsules after depletion of the emulsifying agent (i.e. cholate), coating with the ABA block copolymer, Tetronic-908 was studied. After Tetronic-908 treatment at concentrations that were harmless to cultured cells, the clustering of the microcapsules was prevented, the adsorption of opsonins was decreased and the attachment to cells was inhibited, but the oxygen transport capacity of PLGA microcapsules was even increased. The present data clearly show that perfluorodecalin-filled PLGA microcapsules must be coated before decreasing the emulsifying agent cholate to physiological concentrations, in order to develop a solution that has the capabilities to function as a potential artificial oxygen carrier suspension.     

胎儿骨髓间充质干细胞复合PLGA支架的形态学观察

目的 探讨胎儿骨髓间充质干细胞(fetal bone marrow mesenehymal stem cells，fBMSCs)与低热高压法制作的聚丙交酯-乙交酯(PLGA)支架材料复合培养。构建组织工程化骨的可行性。方法 预制PLGA支架材料，取5月胎儿肱骨和股骨骨髓，用单核细胞分离液分离fBMSCs，含双抗的低糖DMEM原代和传代培养，倒置显微镜下观察细胞生物学特性，用F1TC标记的抗CDl05、CD44和用PE标记的抗CD34、CD29对第4代细胞进行流式细胞鉴定，并与PLGA支架材料复合培养l周后行扫描电镜观察。结果原代及传代培养的fBMSCs增殖较迅速，第4代CD105阳性细胞占84．08％，CD29阳性细胞占88．77％，CD44阳性细胞占89．53％。复合PLGA支架材料细胞生长状态良好。结论 骨髓间充质干细胞(bone mesenchymal stem cells，BMSCs)是骨组织工程适宜的种子细胞，与低热高压制作的PLGA支架材料复合可体外构建组织工程骨。     

酸性可调的聚乳酸-羟基乙酸共聚物微球的制备

目的制备具有酸性自中和能力的聚乳酸-羟基乙酸共聚物[Poly(lactic-co-glycolic acid),PLGA]微球,用于可注射组织工程支架材料或药物释放。方法用二次乳化的方法,将具有缓冲能力的三聚磷酸盐(TPP)包埋于PLGA微球内,制备出PLGA/TPP的复合微球。结果PLGA与TPP以64:1的摩尔比混合时,所制备的PLGA/TPP微球在降解过程中能很好地维持pH值中性,在降解28 d后周围pH值仍为6.93,远高于同样条件下单纯PLGA降解时周围的pH值6.66(P<0.05)。TPP盐颗粒的量对PLGA微球的降解影响很大,当TPP的量增加到12:1时,降解时的酸性要比单纯PLGA微球更为严重,在降解28 d后的pH值低于纯的PLGA微球,仅为6.35(P<0.05)。结论具有缓冲能力的TPP的适量加入,能够有效地调节PLGA微球在降解过程中所产生的酸,从而缓解周围环境pH值下降的问题,但当TPP的量超过一定值时,反而加快PLGA微球的降解。     

复合三联抗结核药聚乳酸-羟基乙酸缓释微球的制备及体外释药特性

目的 :制备复合异烟肼(H)、利福平(R)、吡嗪酰胺(Z)的聚乳酸-羟基乙酸(HRZ/PLGA)缓释微球,观察其理化性质和体外缓释特性。方法:以PLGA(450mg)为载体,避光条件下称取H(40mg)、R(60mg)、Z(125mg),采用复乳-溶剂挥发法制备HRZ/PLGA缓释微球,应用扫描电镜观察微球的形态特征;应用高效液相色谱法(HPLC)测定其载药量、包封率;采用溶出法、HPLC于3h、6h、12h、1d、2d、3d、6d、9d、12d、15d、20d、25d、30d、40d、50d测定H、R、Z三种药物的浓度,观察其是否均大于10倍最低抑菌浓度(MIC),计算其日均释药率、累计释药率。结果:HRZ/PLGA微球在电镜下观察呈圆球形,平均粒径为10.3±4.7μm;H、R、Z三种药物的载药量分别为(18.02±0.36)%、(22.46±0.24)%、(21.68±0.37)%,包封率分别为(54.79±1.13)%、(72.35±0.39)%、(67.21±0.68)%;体外缓释试验显示微球缓释前12d左右,三种药物的累计缓释度均超过了50%,日均释药率分别为5.05%、4.89%、6.86%;第12天后三药的缓释基本趋于稳定,日均释药率分别为0.17%、0.26%、0.16%;三种药物缓释到50d时均大于10倍MIC。结论:HRZ/PLGA微球具有优良的载药及药物缓释效果,是一种理想的复合抗结核药物缓释系统。     

PLGA–PTMC–Cultured Bone Mesenchymal Stem Cell Scaffold Enhances Cartilage Regeneration in Tissue‐Engineered Tracheal Transplantation

The treatment of long‐segment tracheal defect requires the transplantation of effective tracheal substitute, and the tissue‐engineered trachea (TET) has been proposed as an ideal tracheal substitute. The major cause of the failure of segmental tracheal defect reconstruction by TET is airway collapse caused by the chondromalacia of TET cartilage. The key to maintain the TET structure is the regeneration of chondrocytes in cartilage, which can secrete plenty of cartilage matrices. To address the problem of the chondromalacia of TET cartilage, this study proposed an improved strategy. We designed a new cell sheet scaffold using the poly(lactic‐co‐glycolic acid) (PLGA) and poly(trimethylene carbonate) (PTMC) to make a porous membrane for seeding cells, and used the PLGA–PTMC cell‐scaffold to pack the decellularized allogeneic trachea to construct a new type of TET. The TET was then implanted in the subcutaneous tissue for vascularization for 2 weeks. Orthotopic transplantation was then performed after implantation. The efficiency of the TET we designed was analyzed by histological examination and biomechanical analyses 4 weeks after surgery. Four weeks after surgery, both the number of chondrocytes and the amount of cartilage matrix were significantly higher than those contained in the traditional stem‐cell–based TET. Besides, the coefficient of stiffness of TET was significantly larger than the traditional TET. This study provided a promising approach for the long‐term functional reconstruction of long‐segment tracheal defect, and the TET we designed had potential application prospects in the field of TET reconstruction.     

携载rhBMP-2微球的新型可注射自凝固复合人工骨的制备及特性研究

[目的]制备一种具有良好降解性和成骨活性、可注射的自凝固新型骨修复材料。[方法]制备携载rhBMP-2的聚乳酸与聚乙醇酸共聚物（PLGA）微球，并将其与rhBMP-2／磷酸钙骨水泥（CPC）复合，制备出rhBMP-2／PLGA微球／CPC复合人工骨。探讨了材料的特性，包括形貌、固化时间、抗压强度及反映材料体外降解速度的指标一体外降解液Ca、P浓度变化，测定复合材料rhBMP乏的释药速度及体外诱导MSCs细胞成骨分化的能力。[结果]与单纯CPC-rhBMP-2相比，复合材料的固化时间少量增加，抗压强度下降明显。体外降解速度及体外释药明显提高，释放的rhBMP-2具有骨诱导活性。[结论]rhBMP-2／PLGA微球／磷酸钙骨水泥新型复合人工骨是具有良好应用前景的骨修复材料。     

以冻干骨为平台重建组织工程化关节软骨的研究

目的:探索在兔冻干异体骨关节平台上利用组织工程的方法再造人工关节软骨的可行性。方法:实验分成四组,运用组织工程方法将不同构成的同种异体兔软骨细胞-支架材料复合物种植于兔冻干异体骨关节平台上,植入实验兔体内,3月后取材观察体内成软骨情况。结果:仅种植兔软骨细胞的冻干骨关节支架上未见新生软骨形成。粘合有种植兔软骨细胞的PLGA膜片的冻干骨支架关节腔内见新生类软骨样物出现。自体软骨层孔洞缺损模型使用软骨细胞-PLGA膜片复合物可修复软骨缺损。结论:软骨细胞-PLGA膜片复合物实验动物关节内可形成软骨样物;但在冻干骨关节平台上尚不能形成有功能意义的关节软骨层。     

曲安奈德PLGA微球对兔上腭部创面瘢痕形成影响的实验研究

目的:探讨曲安奈德PLGA微球对创面瘢痕愈合中瘢痕生成的抑制作用,研究局部应用曲安奈德的最佳给药途径。方法:3组共24只兔的上腭部创面模型,分别应用曲安奈德PLGA微球以及曲安奈德悬浊液,在瘢痕形成不同时间后切取瘢痕标本进行HE、VG染色及酶组织化学染色并电镜观察其组织形态学改变来分析曲安奈德不同给药途径的差异。结果:三组兔上腭创面愈合时间不同,表面颜色、质地不一样。电镜、常规染色以及免疫组织化学染色皆说明曲安奈德PLGA微球有明显的瘢痕抑制作用,且效果高于曲安奈德悬浊液。结论:曲安奈德PLGA微球能抑制瘢痕的增殖过程,使瘢痕组织纤维化过程明显减轻。合并手术一次性给药治疗瘢痕有很好的临床价值。